Budigalimab

AUG 14, 2026 · PHASE 1/2 TRIAL

Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations

ClinicalTrials.gov

This is a Phase 1/2 trial registration with no posted results; it describes a planned dose-escalation and optimization study in a treatment-naive population, representing early-stage investigation of a novel combination.